MRNA — Moderna, Inc. - Common Stock
Session close: $202.63. Regular-session share volume: 48,189,321. Change from previous close: -17.57%.
Key developments
Reporting linked Moderna’s selloff, despite broader healthcare gains, to an alleged melanoma vaccine data leak suggesting less benefit than an earlier study and raising questions about added value over existing immunotherapy. The leaked findings were not independently verified, and differences between trials limit comparisons.
Moderna stock crashes as leaked melanoma data threatens its record August rally · Why Is Moderna Stock Sinking Thursday?
Later in the session, Moderna and Merck announced positive recurrence-free and distant metastasis-free survival results for their personalized cancer therapy combined with Keytruda, though the supplied excerpt contains limited detail. Separate coverage noted bird flu vaccine progress and a Jefferies target increase without establishing their trading impact.
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium · Why Is Moderna Stock Sinking Thursday? · Jefferies Adjusts Price Target on Moderna to $215 From $150 · Moderna (MRNA) Starts Late Stage Trial For mRNA Bird Flu Vaccine · Is Moderna (MRNA) Fully Valued Following Its NASDAQ 100 Inclusion?
In the limited, unverified X sample, ThomasVioli framed the reaction as expectations risk, while zethedeuce emphasized potential patient benefits if results replicate across cancers. These posters’ interpretations neither verify efficacy nor establish the selloff’s cause.
Source post by @zethedeuce · Source post by @ThomasVioli · Source post by @ThomasVioli
News sources
Company news Moderna stock crashes as leaked melanoma data threatens its record August rally · Company news Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42% · Company news Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium · Company news Moderna Stock Plummets 25% After Cancer-Vaccine Data Leak · Company news Why Is Moderna Stock Sinking Thursday? · Company news Moderna and Merck Shares Decline Following Potential Melanoma Vaccine Data Leak · Company news Moderna shares plunge on cancer vaccine data leak · Company news Moderna, Merck Shares Fall After Possible Melanoma Data Leak · Company news Watching Moderna; Shares Continue Seeing Downside Volume Following Alleged Leak Of ESMO 2026 Abstract With Melanoma Vaccine Trial Data Evaluating Intismeran Autogene/Keytruda Combo Showing Reduced Risk Of Recurrence/Death By 42% · Company news Watching Moderna; Shares Plunge ~15% After Popular YouTuber TOGI Reveals Full-Portfolio Put Position Against The Stock · Company news Jefferies Adjusts Price Target on Moderna to $215 From $150 · Company news Moderna (MRNA) Starts Late Stage Trial For mRNA Bird Flu Vaccine · Company news Is Moderna (MRNA) Fully Valued Following Its NASDAQ 100 Inclusion? · Company news Moderna (MRNA) Rises Higher Than Market: Key Facts